Medical University of Vienna, Department of Pediatrics and Adolescent Medicine, Vienna, Austria.
BioMarin Pharmaceutical Inc., Novato, CA, USA.
Mol Genet Metab. 2018 Jul;124(3):184-188. doi: 10.1016/j.ymgme.2018.05.003. Epub 2018 May 16.
For decades, intracerebroventricular (ICV), or intraventricular, devices have been used in the treatment of a broad range of pediatric and adult central nervous system (CNS) disorders. Due to the limited permeability of the blood brain barrier, diseases with CNS involvement may require direct administration of drugs into the brain to achieve full therapeutic effect. A recent comprehensive literature review on the clinical use and complications of ICV drug delivery revealed that device-associated complication rates are variable, and may be as high as 33% for non-infectious complications and 27% for infectious complications. The variability in reported safety outcomes may be driven by a lack of consensus on best practices of device use. Numerous studies have demonstrated that employing strict aseptic techniques and following stringent protocols can dramatically reduce complications. Key practices to be considered in facilitating the safe, long-term use of these devices are presented.
几十年来,脑室内(ICV)或脑室设备已被用于治疗广泛的儿科和成人中枢神经系统(CNS)疾病。由于血脑屏障的通透性有限,因此涉及中枢神经系统的疾病可能需要将药物直接注入大脑才能达到完全的治疗效果。最近对 ICV 药物输送的临床使用和并发症的全面文献回顾显示,与设备相关的并发症发生率各不相同,非感染性并发症的发生率高达 33%,感染性并发症的发生率为 27%。报告的安全结果的可变性可能是由于缺乏关于设备使用最佳实践的共识所致。许多研究表明,采用严格的无菌技术并遵循严格的方案可以显着降低并发症的发生率。提出了促进这些设备安全,长期使用的关键实践。